Anthony M Hunter, MD

Anthony M. Hunter, MD, discusses the role of momelotinib for the treatment of adult patients with myelofibrosis and moderate to severe anemia.

Anthony M. Hunter, MD, discusses the development of, and future roles for JAK, BET, and BCL2/BCL-XL inhibitors in myelofibrosis.

Anthony M. Hunter, MD, discusses challenges associated with ruxolitinib-based toxicities in patients with myelofibrosis.

Anthony M. Hunter, MD, discusses the evolution of pathology in myelofibrosis based on outcomes from clinical trials.

Anthony M. Hunter, MD, discusses the evolution of JAK inhibitors in myelofibrosis, a topic that was highlighted in a presentation at the 2023 SOHO Annual Meeting.

Following the FDA approvals of the JAK inhibitors ruxolitinib, fedratinib, and pacritinib, the treatment landscape of myelofibrosis continues to grow with the use of these agents with an additional FDA review planned for momelotinib in September 2023.

Anthony M Hunter, MD, discusses the current treatment landscape with JAK inhibitors in myelofibrosis.